Leap Therapeutics, Inc.
LPTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.06 | -0.49 | -3.53 |
| FCF Yield | -55.76% | -51.69% | -96.24% | -12.64% |
| EV / EBITDA | -0.87 | -0.18 | -0.56 | -4.04 |
| Quality | ||||
| ROIC | -200.12% | -144.10% | -103.03% | -38.21% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 100.00% |
| Cash Conversion Ratio | 0.89 | 0.54 | 0.90 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | -46.29% |
| Free Cash Flow Growth | -37.82% | 10.79% | -39.50% | -35.44% |
| Safety | ||||
| Net Debt / EBITDA | 0.67 | 0.87 | 0.38 | 2.82 |
| Interest Coverage | 0.00 | 0.00 | -1,051.17 | -1,010.39 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -5,526.29 | 0.00 | 289.32 |